H1N1 FLU BREAKING NEWS: Vaccine news, Microsoft’s online tool

first_img Microsoft offers online flu self-assessmentMicrosoft launched a new Web site today, H1N1 Swine Flu Response Center, to help patients assess flu-like symptoms and decide their next step. The self-assessment is licensed from experts at Emory University. Dr. Arthur Kellermann, professor of emergency medicine at Emory, said in a Microsoft release that the tool “can encourage those who are severely ill or at risk for serious illness to contact their doctor, and reassure everyone else that it is safe and prudent to recover at home.”http://www.microsoft.com/presspass/press/2009/oct09/10-07h1n1responsecenterpr.mspxOct 7 Microsoft news release EU approves Baxter’s cell-based vaccineThe European Commission today approved Baxter International’s pandemic H1N1 vaccine, Celvapan, for use in the European Union, the company announced. It is the first cell culture-based H1N1 vaccine as well as the first non-adjuvanted product to win European approval. The EU authorization calls for using two doses of the vaccine in adults and children; the company is awaiting trial results to determine if one dose will be sufficient in adults.http://www.baxter.com/press_room/press_releases/2009/10_07_09-celvapan.htmlOct 7 Baxter news release Oct 7, 2009 Study: Seasonal vaccine may help fight H1N1Contrary to most other evidence, a study from Mexico suggests that seasonal flu vaccine may offer some protection against the novel H1N1 virus. Researchers compared the vaccination status of 60 H1N1 case-patients and 180 control patients at a specialty hospital. The H1N1 patients were less likely to have had a seasonal flu shot. But the authors say the study is limited by its small size, retrospective design, and the high prevalence of vaccination and chronic conditions in the control group.http://www.bmj.com/cgi/content/full/339/oct06_2/b3928Oct 6 British Medical Journal study Novartis ships seasonal, H1N1 vaccines to USVaccine manufacturer Novartis said yesterday it has completed shipments of its seasonal flu vaccine, Fluvirin, to the United States after delivering 27 million doses. The Swiss company originally had said it planned to supply about 30 million doses to the US market. Yesterday the firm also said it started shipping swine flu vaccine on Sept. 27, 2 weeks after the formulation received approval from the US Food and Drug Administration.http://www.novartis.com/newsroom/media-releases/en/2009/1345850.shtmlOct 6 Novartis press releaselast_img

Leave a Reply

Your email address will not be published. Required fields are marked *